HCPLive Network

Drug Reduces Brain Lesions in Multiple Sclerosis

Tuesday, April 17 (HealthDay News) -- As part of a Phase 2 trial, Timothy Vollmer, M.D., from the University of Colorado in Denver, and colleagues randomly assigned 407 patients with relapsing-remitting MS to placebo or one of three doses of ONO-4641 (0.05 mg, 0.10 mg, or 0.15 mg) once a day for 26 weeks. Participants were aged 18 to 55 years and had Expanded Disability Status Scale scores up to 5.5.

Based on brain scans performed every four weeks starting at week 10, the researchers found that, compared with placebo, there was a reduction in gadolinium-enhancing lesions of 82 percent for the 0.05 mg dose, 92 percent for the 0.10 mg dose, and 77 percent for the 0.15 mg dose. Adverse events appeared to be dose related and included cardiovascular events, liver enzyme elevations, and grade 4 lymphopenia.

"ONO-4641 demonstrated statistically significant efficacy on key end points, compared to placebo, and was well tolerated in patients with relapsing-remitting MS," Vollmer and colleagues conclude.

The study was supported by Ono Pharmaceutical Co., Ltd., which developed ONO-4641.

Press Release
More Information

An experimental drug, ONO-4641, which is an oral sphingosine-1-phosphate receptor agonist, reduces the number of brain lesions in patients with relapsing-remitting multiple sclerosis, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.

Copyright © 2012 HealthDay. All rights reserved.


Further Reading
Provocative research raises the question of whether we should we look at Alzheimer’s disease as “type 3 diabetes.”
For stroke survivors, annual direct costs are comparable at 10 years and between 3 to 5 years for ischemic stroke but are higher at 10 years after hemorrhagic stroke, according to a study published online Oct. 23 in Stroke.
How can clinicians help veterans with PTSD deal with depression and anxiety symptoms, and process intense feelings of shame and guilt stemming from actions and situations they experienced while serving?
Targets of workplace bullying can offer chaos, report, or quest narratives about their experiences, and coworker response plays a role in narrative development, according to a study published online Sept. 25 in Management Communication Quarterly.
Hypoglycemia related to type 2 diabetes mellitus (T2DM) doesn't appear to impact brain pathology, according to a study published online Sept. 29 in Diabetes Care.
After weight-loss surgery, some patients may be at risk for developing severe headaches, a new study suggests. The report was published online Oct. 22 in Neurology.
The US health care system ranks last compared to other industrialized nations when it comes to affordability and patient access, according to a new survey published in the Oct. 23 issue of the New England Journal of Medicine.
More Reading